Circulating Irisin Levels Are Not Regulated by Nutritional Status, Obesity, or Leptin Levels in Rodents

Mar Quiñones,1,2 Cintia Folgueira,1,2,3 Estrella Sánchez-Rebordelo,1,2 and Omar Al-Massadi1,2

1Department of Physiology, CIMUS, University of Santiago de Compostela, Sanitary Research Institute of Santiago de Compostela (IDIS), 15782 Santiago de Compostela, Spain
2CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 15706 Santiago de Compostela, Spain
3Endocrine Physiopathology Group, Sanitary Research Institute of Santiago de Compostela (IDIS), University Hospital Complex of Santiago (CHUS/SERGAS), 15706 Santiago de Compostela, Spain

Correspondence should be addressed to Omar Al-Massadi; omar.al-massadi@usc.es

Received 20 May 2015; Revised 19 August 2015; Accepted 6 September 2015

Academic Editor: Aaron L. Sverdlov

Copyright © 2015 Mar Quiñones et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Irisin is a cleaved and secreted fragment of fibronectin type III domain containing 5 (FNDC5) that is mainly released by skeletal muscle and was proposed to mediate the beneficial effects of exercise on metabolism. In the present study we aim to investigate the regulation of the circulating levels of irisin in obese animal models (diet-induced obese (DIO) rats and leptin-deficient (ob/ob) mice), as well as the influence of nutritional status and leptin. Irisin levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA) and Radioimmunoassay (RIA). Serum irisin levels remained unaltered in DIO rats and ob/ob mice. Moreover, its circulating levels were also unaffected by fasting, leptin deficiency, and exogenous leptin administration in rodents. In spite of these negative results we find a negative correlation between irisin and insulin in DIO animals and a positive correlation between irisin and glucose under short-term changes in nutritional status. Our findings indicate that serum irisin levels are not modulated by different physiological settings associated to alterations in energy homeostasis. These results suggest that in rodents circulating levels of irisin are not involved in the pathophysiology of obesity and could be unrelated to metabolic status; however, further studies should clarify its precise role in states of glucose homeostasis imbalance.

1. Introduction

The combination of energy-dense diets and sedentary lifestyles has accelerated the incidence of obesity and its comorbidities including dyslipidemia, diabetes mellitus, and cardiovascular disease. Inflammatory processes play a crucial role in the development of obesity. Adipose tissue release cytokines such as IL-6 and IL-1β in obesity that targets several tissues such as the heart, the pancreas, or the liver [1]. Physical inactivity causes accumulation of visceral fat that induces systemic low grade inflammation and in turn exercise promotes a variety of metabolically beneficial effects in the organism [2]. However, its mechanism of action remains elusive and many efforts are focused to characterize new molecular targets or mediators of these healthy benefits. The skeletal muscle is considered nowadays as a complete endocrine organ [3] and there are more than 1000 genes activated by exercise [4]. One of these proposed mediators is the peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1-α), a transcriptional coactivator released by the muscle that induces mitochondrial biogenesis and thus thermogenesis [5, 6] as well as modulating glucose, lipid, and energy homeostasis [7, 8]. PGC1-α induces the expression of the fibronectin type III domain containing 5 (FNDC5) gene that is cleaved and secretes a new hormone from skeletal muscle named irisin [8]. FNDC5 was simultaneously characterized in 2002 by two independent groups [9, 10], but it was ten years later when irisin attracted more interest because it was reported to act as a mediator of the beneficial effect of exercise [8], increasing metabolic
uncoupling and caloric expenditure and promoting browning [8, 11, 12], resulting in an improvement of obesity and glucose homeostasis. However, further studies performed in animals and humans reported controversial results and the physiological role of irisin is still under debate [2, 8, 13–18].

On the other hand, several studies assessed circulating levels of irisin in humans and found controversial results because some of them reported an increase of irisin under conditions of obesity [19, 20] while others found a negative association between irisin levels and obesity [21]. Furthermore, no association was found between these two parameters in humans [22]. Accordingly, circulating irisin levels decreased after surgical [23] or dietary-induced [24] weight loss. In rodents, gene expression results showed that skeletal muscle FNDC5 mRNA levels were proportional to circulating leptin levels [25] and the regulation of FNDC5 expression in DIO animals was different depending on the fat depot [26]. However, there are no data on circulating irisin levels in obese rodents and its regulation under certain physiological conditions associated to body weight changes is very scarce. The aim of this study was to assess the regulation of serum irisin levels by nutritional status, leptin, and diet-induced obesity in rodents.

2. Material and Methods

2.1. Animals. Male Sprague-Dawley rats (bred in the Ani-

calorio Xeral of USC; Santiago de Compostela, Spain) and ob/ob mice (Charles River, Barcelona, Spain) were housed under conditions of controlled illumination (12:12-h light/dark cycle), humidity, and temperature. Animals were fed with a standard diet (Scientific Animal Food & Engi-

eering, proteins 16%, carbohydrates 60%, and fat 3%) and 
tap water ad libitum unless otherwise indicated. The animals 

were sacrificed in a room separate from other experimental 

animals, and blood samples were centrifuged at 1500 g for 

10 min and the serum was harvested and stored at −80°C until 
an analysis could be performed. All experimental procedures 

were reviewed and approved by the Ethics Committees of 
the University of Santiago de Compostela in accordance 
with the institutional guidelines and in strict compliance 
with the European Union normative for the care and use 
of experimental animals. The number of animals used in each 

experimental setting is indicated in the corresponding figure's 
caption.

2.2. Experimental Setting 1: Effect of the Diet on Serum Irisin 

Levels. After weaning, 6-week-old male Sprague-Dawley rats 

were either fed a high-fat (HF) diet (60% by energy) or a 

low-fat (LF) diet (10% by energy) (reference #: D12492 and 

D12450B resp., Research Diets, NJ, US) for 10 weeks.

2.3. Experimental Setting 2: Effects of Food Deprivation 

on Serum Irisin Levels. 10-week-old male rats were deprived 

of food for 48 h, or refed for 24 h after fasting while the control 

group was fed ad libitum [27, 28]. All animals had free access 
to tap water.

2.4. Experimental Setting 3: Effects of Leptin on Serum Irisin 

Levels. The effects of systemic leptin administration on

serum irisin levels were studied in leptin deficient mice 

(ob/ob mice). Leptin-deficient animals were referred to wild 
type (WT) control animals and were distributed in three 
groups: (a) i.p. vehicle fed ad libitum, (b) i.p. vehicle after 36 h 
fasting, and (c) i.p. leptin in fed ad libitum mice. Animals were 
treated with recombinant leptin (L-4146, Sigma-Aldrich) at 
a dose of 0.5 mg/kg of body weight every 6 h for 3 days 
(intraperitoneal injection) [29].

2.5. Measurement of Body Composition. Body composition 

(fat and lean mass) was assessed using Nuclear Magnetic Re-

sonance imaging system (Whole Body Composition Analyzer; 
EchoMRI, Houston, USA) as previously shown [30, 31].

2.6. Measurement of Biochemical and Hormonal Parameters. 

Irisin and insulin levels were determined by ELISA using 

reagents kits and methods provided by Phoenix Pharma-

caceuticals Inc. and by Millipore corporation, respectively. 

These kits are suitable for human, rats, and mice and were 

used in previous studies [20, 24, 32–34]. The quantitative 

measurement of irisin in serum samples was performed using 
a commercial ELISA kit directed against amino acids 33–142 
of the FNDC5 protein (Irisin ELISA Kit EK-067-52; Phoenix 

Pharmaceuticals Inc., CA) according to the manufacturer’s 

instructions. The absorbance from each sample was measured 
in duplicate using a spectrophotometric microplate reader 
at wavelength of 450 nm (Versamax Microplate Reader; 

Associates of Cape Cod Incorporated, East Falmouth, MA). 

The intra- and interassay coefficients of variation for the 

kit were 4–6% and 8–10%, respectively. Irisin levels were 
determined also by RIA using reagents kits and methods 
provided by Phoenix Pharmaceuticals Inc. (Belmont, CA; 
Cat. No. RK-067-16). For testing serum irisin levels, the 
samples were obtained from trunk blood by decapitation and 

were collected in tubes for serum separation (BD Vacutainer 
SST II Advance). Results were expressed as ng per milliliter 
of irisin in serum. Serum samples were tested in duplicate 
within one assay, and the results were expressed in terms of 
the rat irisin standard (ng/mL).

The absorbance from each sample with regard to insulin 

levels was measured in duplicate using a spectrophotometric 

microplate reader at wavelength of 450 nm and 590 nm. The 

intra- and interassay coefficients of variation for the kit were 
1–4% and 6–9%, respectively. Serum samples were tested in 
duplicate within one assay, and the results were expressed in 
terms of the rat insulin standard (ng/mL).

Glucose and total cholesterol was determined using 

colorimetric assays (Spinreact, Girona, Spain) as previously 
described [35].

2.7. Western Blot Analysis. Western blot was performed as 

previously described [36, 37]. White adipose tissue (WAT) 

and brown adipose tissue (BAT) were dissected and stored 
at −80°C until further processing. 

WAT and BAT were homogenized in ice-cold lysis buffer 

containing 50 mmol/L Tris-HCl (pH 7.5), 1 mmol/L EGTA, 
1 mmol/L EDTA, 1% Triton X-100, 1 mmol/L sodium ortho-

vanadate, 50 mmol/L sodium fluoride, 5 mmol/L sodium 

pyrophosphate, 0.27 mol/L sucrose, 0.1% 2-mercaptoethanol,
and complete protease and phosphatase inhibitor cocktail (1 tablet/50 mL; Roche Diagnostics, Mannheim, Germany). Homogenates were centrifuged at 13,000 g for 10 min at 4°C, supernatants were removed, and aliquots were stored in −80°C.

WAT and BAT lysates were subjected to SDS-PAGE gels. Briefly, total protein lysates from WAT and BAT (20 μg) were subjected on 8% and 12% of SDS polyacrylamide gels and electrotransferred on a polyvinylidene difluoride membrane. Membranes were blocked for 1 h in TBS-Tween 20 (TBST: 50 mmol/L Tris-HCl [pH 7.5], 0.15 mol/L NaCl, and 0.1% Tween 20) containing 3% BSA and probed with for 16 h at 4°C in TBST, 3% BSA in the indicated antibodies: IL-6 (ab-9722) (Abcam, Cambridge, UK); PGC1α (sc-13067) (Santa Cruz Biotechnology, Santa Cruz, CA), β-tubulin (T-5168), and β-actin (A-5316) (Sigma-Aldrich). For protein detection we used horseradish peroxidase-conjugated secondary antibodies (Daku Denmark, Glostrup, Denmark) and chemiluminescence (Pierce ECL Western Blotting Substrate, Thermo scientific, USA). Then, the membranes were exposed to X-ray film (Super RX, Fuji Medical X-Ray Film, Fujifilm, Japan) and developed with developer and fixing liquids (AGFA, Germany) under appropriate dark conditions. We used seven samples per group and the protein levels were normalized to β-actin (WAT) and to α-tubulin (BAT) for each sample.

### 2.8. Statistics

The results are shown as the mean ± standard error of mean. Statistical analysis was performed using Student’s t-test (when two groups were analysed) or one-way ANOVA followed by a post hoc multiple comparison test (Tukey Test) (when more than two groups were analysed). A P value less than 0.05 was considered statistically significant; Graph Prism software (San Diego, CA) was used for the data analysis. For correlation studies statistical analyses were performed using SPSS version 20.0 software statistical package (SPSS, Chicago, IL). The relationships between variables were analyzed by Pearson’s correlation (normally distributed data) or Spearman’s rank correlation (nonnormally distributed data) coefficients (r). A P value less than 0.05 was considered statistically significant.

### 3. Results

As expected, the higher body weight in rats fed HF diet (Figure 1(a)) was consistent with a significant increase in fat and lean mass index compared to LF diet fed rats (Table 1) and a significant increase in proteins levels of IL-1β in WAT but not of IL-6 (Figure 2(a)). We do not have a clear explanation for this fact but it could be due to the limited time of exposition to the diet (10 weeks) or because a total positive correlation between IL-6 and obesity is not always a strong proof, due to the fact that a lack of IL-6 has been shown to cause obesity and insulin resistance in rodents [38]. However, the DIO rats eat less amount of food than the LF diet fed rats because the HF diet is a hypercaloric food and these rats need less quantity of food to be satiated compared to hypocaloric LF diet fed animals (Figure 1(e)). Correspondingly, these DIO rats are hyperglycemic and hyperinsulinemic (Table 1) and display a trend of high cholesterol levels although this trend is not significant (Table 1), as previously described [22]. With regard to the monogenic model of obesity, the ob/ob mice exhibit a high body weight (Figure 1(b)) and food intake (Figure 1(f)), and similar to the DIO rats, the ob/ob mice display a significant increase in insulin, glucose, and cholesterol levels with respect to WT controls (Table 1) and high levels of inflammatory markers in WAT (Figure 2(b)). Furthermore, we measure the levels of these biochemical and hormonal parameters in the serum of rats submitted to short-term changes in nutritional status. As expected, a 48 h fasting induces a significant decrease in glucose and insulin serum levels compared to ad libitum fed animals and a significant increase in total cholesterol levels (Table 1) [39, 40].

Since circulating irisin levels are increased in human obesity [19, 20], we assessed serum irisin levels in two animal obese models: DIO rats as a model of polygenic obesity and ob/ob mice as a model of monogenic obesity. In both rodent obese models, serum irisin levels remained unaltered. Rats fed a HF diet showed similar serum irisin levels as animals fed a LF diet during 10 weeks (Figure 3(a)). Interestingly, these results are consistent with a recent study in humans [22]. Similarly, circulating irisin levels remained unaltered between WT and obese mice lacking leptin (ob/ob mice).

### Table 1: Body composition and biochemical and hormonal characteristics from the models studied.

| Group             | Insulin (ng/mL) | Glucose (mg/dL) | Total cholesterol (mg/dL) | Fat mass (g) | Lean mass (g) |
|-------------------|-----------------|-----------------|---------------------------|--------------|---------------|
| Low fat           | 5.36 ± 1.08     | 18.51 ± 1.02    | 6.32 ± 0.40               | 56.53 ± 5.63 | 412.3 ± 4.0   |
| High fat          | 9.07 ± 1.58*    | 25.86 ± 0.96*** | 7.14 ± 0.92               | 150.02 ± 23.04** | 435.1 ± 5.5** |
| Wild type mice    | 2.01 ± 0.42     | 2.41 ± 0.13     | 0.78 ± 0.07               | —            | —             |
| ob/ob mice FED    | 7.67 ± 1.63**   | 4.40 ± 0.72*    | 1.04 ± 0.03*              | —            | —             |
| ob/ob mice FAST   | 4.35 ± 0.85     | 1.94 ± 0.34**   | 0.088 ± 0.04              | —            | —             |
| ob/ob mice FED + OB | 1.32 ± 0.97*** | 3.24 ± 0.56     | 0.087 ± 0.02              | —            | —             |
| Rats FED          | 1.11 ± 0.22     | 20.16 ± 2.09    | 5.09 ± 0.83               | 26.21 ± 0.88 | 175.6 ± 3.4   |
| Rats FAST         | 0.09 ± 0.007**  | 13.23 ± 0.71**  | 8.20 ± 0.32**             | 21.94 ± 0.71* | 163.5 ± 1.9*  |
| Rats REFED        | 1.13 ± 0.19**   | 26.12 ± 0.78**  | 6.14 ± 0.34**             | 23.52 ± 1.13 | 166.6 ± 3.4   |

Values are mean ± SEM of 7-8 animals per group. *P < 0.05; **P < 0.01; ***P < 0.001 versus controls. #P < 0.05; ##P < 0.01; ###P < 0.001 versus ob/ob FED and versus FAST 48 h.
Figure 1: Continued.
FIGURE 1: Body weight and food intake. (a) Body weight of rats fed with high fat (HF) and low fat (LF) diet. (b) Body weight in leptin deficient mice (ob/ob) versus wild type (WT) mice fed ad libitum. (c) Body weight in ob/ob mice fed ad libitum, 36 hours fasted and after leptin treatment in ob/ob mice fed ad libitum. (d) Body weight change in rats fed ad libitum, in 48 h of fasting and in rats submitted to a refeeding for 24 h after 48 h of fasting. (e) Food intake of rats fed with high fat (HF) and low fat (LF) diet. (f) Food intake in leptin deficient mice (ob/ob) versus wild type (WT) mice fed ad libitum. (g) Food intake in ob/ob mice fed ad libitum, 36 hours fasted and after leptin treatment in ob/ob mice fed ad libitum. (h) Food intake in rats fed ad libitum, in 48 h of fasting and in rats submitted to a refeeding for 24 h after 48 h of fasting. Values are mean ± standard error of the mean of 6–12 animals per group. Values are mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 versus controls and #P < 0.05; ##P < 0.01; ###P < 0.001 versus FAST 48 h.

Finally, we have also performed correlations studies between serum irisin versus body composition parameters and biochemical and hormonal levels (Figures 4 and 5; Table 2). We do not find any correlation between fat mass, lean mass, or cholesterol levels and irisin in the different models studied (Figures 4(a), 4(b), 4(c), and 4(d); Figures 5(a), 5(c), 5(d), 5(e), 5(f), 5(h), and 5(i); Table 2); however, we detect a negative correlation between irisin and insulin in the DIO model (Figure 5(b); Table 2) as previously described in humans [21] and a positive correlation between glucose and irisin under short-term changes in nutritional status (Figure 5(g); Table 2).

4. Discussion

The discovery of irisin has created a great expectation due to its proposed beneficial metabolic effects. However, the knowledge about irisin regulation and secretion is still scant and the results are controversial. In this sense, the levels of circulating irisin in obesity have been reported to be negatively associated to obese men [21], whereas others indicated that irisin levels are high in obese individuals or are positively correlated to body mass index [19, 20, 23, 43]. In rodents, the results are equally ambiguous, as it was shown that serum irisin levels are decreased in obese Otsuka Long-Evans Tokushima Fatty (OLETF) rats in comparison to lean rats [25], and in obese Zucker rats [26] but increased in DIO rats [26]. In the current study, we have analyzed serum irisin levels in two different obese animal models, DIO rats as a model of polygenic obesity and in ob/ob mice as a model of monogenic obesity. In both cases, our results were identical,
as we did not detect any significant difference between lean and obese animals in concordance with a study in obese humans [22]. Although all these results obtained in different models of obese animals do not point in the same direction, it is important to highlight that each model is associated with different metabolic alterations that might affect irisin levels. For instance, OLETF rats are diabetic whereas DIO rats are insulin resistant but not diabetic. This is a key issue since the role of irisin on glucose metabolism is still under debate [21, 32, 44, 45]. Another crucial aspect that requires attention is the methodology used for the measurement of irisin. These methodological aspects are likely affecting the results in DIO rats. In this sense, the study of Roca-Rivada and colleagues assessed serum irisin levels by Western blot [26] whereas we used a radioimmunoassay-based method. In spite of these discrepancies between different animal models or methodologies, our present results suggest that circulating irisin levels are not affected by obesity in rodents.

Since obese rodents represent models with long-term metabolic alterations and compensatory mechanisms, we
next evaluated if irisin levels might be affected in situations of metabolic alterations at short term. The nutritional status induces changes in a variety of endocrine axis and if irisin has been proposed as a metabolic regulator, we hypothesized that it should be regulated by fasting. However, we failed to find any change in serum irisin levels by caloric restriction or refeeding, indicating that its circulating levels are not affected by nutritional status. Our findings are in agreement with a previous study indicating that weight loss induced by caloric restriction did not regulate circulating irisin levels in rats [46]. On the other hand both fasting and caloric restrictions are associated to a number of metabolic alterations, and one of the most relevant is the decreased leptin levels. Previous works have suggested a possible cross talk between leptin and irisin because irisin levels are associated with leptin in humans and rats [21, 25], and leptin increases

| Group         | Insulin (ng/mL) | Glucose (mg/dL) | Total cholesterol (mg/dL) | Fat mass (g) | Lean mass (g) |
|---------------|----------------|-----------------|---------------------------|--------------|---------------|
| DIO           | $r = -0.668$   | $r = -0.213$    | $r = 0.288$               | $r = -0.213$ | $r = -0.213$  |
|               | $P = 0.005^{**}$ | $P = 0.446$    | $P = 0.299$               | $P = 0.446$  | $P = 0.446$   |
| ob/ob mice    | $r = 0.045$    | $r = 0.06$      | $r = -0.229$             | —            | —             |
|               | $P = 0.818$    | $P = 0.974$     | $P = 0.242$              | —            | —             |
| FED-FAST-REFED | $r = 0.250$    | $r = 0.432$     | $r = -0.123$             | $r = -0.250$ | $r = 0.040$   |
|               | $P = 0.262$    | $P = 0.045^{*}$ | $P = 0.587$              | $P = 0.261$  | $P = 0.859$   |

Statistical significance is from Pearson (normally distributed data) and from Spearman (nonnormally distributed data) correlation test.

**Table 2:** Correlations of irisin with body composition and biochemical and hormonal parameters from the models studied.
mRNA expression of PGC1-α [41, 42], the proposed upstream regulator of irisin [8]. Moreover recently it was shown that leptin treatment slightly upregulates circulating irisin levels in ob/ob mice [47]. Therefore, we decided to investigate in depth the possible specific interaction between leptin and irisin. In order to test this interaction, we measured irisin levels in a model of hypoleptinemia performing a leptin replacement in ob/ob mice. Our data indicate that circulating levels of irisin remained unaltered after leptin administration in those mice in any experimental group. Therefore, these results suggest that serum irisin levels are not modulated by leptin on our experimental paradigms. Finally, we perform correlation studies of irisin with body composition, biochemical and hormonal parameters. In concordance with our previous results we do not find any correlation between them in most of the parameters studied (Figures 4(a), 4(b), 4(c), and 4(d); Figures 5(a), 5(c), 5(d), 5(e), 5(f), 5(h), and 5(i); Table 2); however, in spite of these negative results we detect a negative correlation between irisin and insulin in DIO animals as previously described in obese subjects [21].

**Figure 4**: Correlation of irisin levels with body composition parameters. Correlation of irisin with lean mass (a) and fat mass (b) in DIO animals and with lean mass (c) and fat mass (d) in short-term changes of nutritional status.
Figure 5: Correlation of irisin levels with biochemical and hormonal parameters. Correlation of irisin with glucose (a), insulin (b), and cholesterol (c) in DIO animals; with glucose (d), insulin (e), and cholesterol (f) in ob/ob mice; with glucose (g), insulin (h), and cholesterol (i) under short-term changes of nutritional status.
and a positive correlation between irisin and glucose under short-term changes in nutritional status (Figures 5(b) and 5(g); Table 2). These data indicate that irisin could play a role in states that involve impairments of glucose homeostasis.

In summary, we conclude that serum irisin levels seem in light of our present results not affected by obesity, nutritional status, or leptin in rodents. However, it is important to note that a limitation of the interpretation of the present results is that the data are based on a direct determination of irisin on serum samples without mechanism exploration or signal transduction studies of irisin with metabolism in obesity models. Further research on irisin will be necessary to clarify its precise role in the regulation of energy balance and its potential therapeutic use in obesity and its comorbidities.

Conflict of Interests

The authors declare that they have no conflict of interests in the authorship or publication of this paper.

Authors’ Contribution

Cintia Folgueira and Estrella Sánchez-Rebordelo contributed equally to this work.

Acknowledgments

Mar Quíñones is a recipient of a Postdoctoral Fellowship from Galician Government (Xunta de Galicia ED481B2014/039-0). Cintia Folgueira is funded by IDIS. Estrella Sánchez-Rebordelo is a fellowship of the Ministerio de Economía y Competitividad (ref. BES-2013-062796). Omar Al-Massadi is funded by the ISCIII/SERGAS thought a research contract “Sara Borrell” (CD14/00091).

References

[1] G. S. Hotamisligil, “Inflammation and endoplasmic reticulum stress in obesity and diabetes,” International Journal of Obesity, vol. 32, supplement 7, pp. S52–S54, 2008.
[2] J. A. Timmons, K. Baar, P. K. Davidsen, and P. J. Atherton, “Is irisin a human exercise gene?” Nature, vol. 488, no. 7413, pp. E9–E11, 2012.
[3] B. K. Pedersen and M. A. Febbraio, “Muscle as an endocrine organ: focus on muscle-derived interleukin-6,” Physiological Reviews, vol. 88, no. 4, pp. 1379–1406, 2008.
[4] P. Keller, N. B. J. Vollaard, T. Gustafsson et al., “A transcriptional map of the impact of endurance exercise training on skeletal muscle phenotype,” Journal of Applied Physiology, vol. 110, no. 1, pp. 46–59, 2011.
[5] K. Baar, A. R. Wende, T. E. Jones et al., “Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1α,” The FASEB Journal, vol. 16, no. 14, pp. 1879–1886, 2002.
[6] J. Lin, H. Wu, P. T. Tarr et al., “Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres,” Nature, vol. 418, no. 6899, pp. 797–801, 2002.
[7] P. Puigserver, Z. Wu, C. W. Park, R. Graves, M. Wright, and B. M. Spiegelman, “A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis,” Cell, vol. 92, no. 6, pp. 829–839, 1998.
[8] P. Boström, J. Wu, M. P. Jedrychowski et al., “A PGC-1α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis,” Nature, vol. 481, no. 7382, pp. 463–468, 2012.
[9] A. Teufel, N. Malik, M. Mukhopadhyay, and H. Westphal, “Frp1 and Frp2, two novel fibronectin type III repeat containing genes,” Gene, vol. 297, no. 1-2, pp. 79–83, 2002.
[10] A. Ferrer-Martínez, P. Ruiz-Lozano, and K. R. Chien, “Mouse PeP: a novel peroxisomal protein linked to myoblast differentiation and development,” Developmental Dynamics, vol. 224, no. 2, pp. 154–167, 2002.
[11] P. Lee, J. D. Linderman, S. Smith et al., “Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans,” Cell Metabolism, vol. 19, no. 2, pp. 302–309, 2014.
[12] Y. Zhang, R. Li, Y. Meng et al., “Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling,” Diabetes, vol. 63, no. 2, pp. 514–525, 2014.
[13] S. Raschke, M. Elsen, H. Gassenhuber et al., “Evidence against a beneficial effect of irisin in humans,” PloS ONE, vol. 8, no. 9, Article ID e73680, 2013.
[14] T. Hofmann, U. Elbelt, A. Ahnis, P. Kobelt, M. Rose, and A. Stengel, “Irisin levels are not affected by physical activity in patients with anorexia nervosa,” Frontiers in Endocrinology, vol. 4, article 202, 2014.
[15] A. Hecksteden, M. Wegmann, A. Steffen et al., “Irisin and exercise training in humans—results from a randomized controlled training trial,” BMC Medicine, vol. 11, article 235, 2013.
[16] M. G. Novelle, C. Contreras, A. Romero-Picó, M. López, and C. Diéguez, “Irisin, two years later,” International Journal of Endocrinology, vol. 2013, Article ID 746281, 8 pages, 2013.
[17] S. Pekkala, P. K. Wiklund, J. J. Hulmi et al., “Are skeletal muscle FNDC5 gene expression and irisin release regulated by exercise and related to health?” Journal of Physiology, vol. 591, no. 21, pp. 5393–5400, 2013.
[18] C. D. Wrann, J. P. White, J. Salogianolis et al., “Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway,” Cell Metabolism, vol. 18, no. 5, pp. 649–659, 2013.
[19] A. Stengel, T. Hofmann, M. Goebel-Stengel, U. Elbelt, P. Kobelt, and B. F. Klapp, “Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity—correlation with body mass index,” Peptides, vol. 39, no. 1, pp. 125–130, 2013.
[20] A. B. Crujeiras, M. Pardo, A. Roca-Rivada et al., “Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women,” American Journal of Human Biology, vol. 26, no. 2, pp. 198–207, 2014.
[21] J. M. Moreno-Navarrete, F. Ortega, M. Serrano et al., “Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 4, pp. E769–E778, 2013.
[22] F. Sanchis-Gomar, R. Alis, H. Pareja-Galeano et al., “Circulating irisin levels are not correlated with BMI, age, and other biological parameters in obese and diabetic patients,” Endocrine, vol. 46, no. 3, pp. 674–677, 2014.
[23] J. Y. Huh, G. Panagiotou, V. Mougiou et al., “FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum
and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise,” *Metabolism: Clinical and Experimental*, vol. 61, no. 12, pp. 1725–1738, 2012.

[24] P. Lopez-Lagarrea, R. de la Iglesia, A. B. Crujeiras et al., “Higher baseline irisin concentrations are associated with greater reductions in glycemia and insulinemia after weight loss in obese subjects,” *Nutrition & Diabetes*, vol. 4, no. 2, article e110, 2014.

[25] M. D. Roberts, D. S. Bayless, J. M. Company et al., “Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats,” *Metabolism: Clinical and Experimental*, vol. 62, no. 8, pp. 1052–1056, 2013.

[26] A. Roca-Rivada, C. Castelao, L. L. Senin et al., “FNDC5/irisin is not only a myokine but also an adipokine,” *PLoS ONE*, vol. 8, no. 4, Article ID e60563, 2013.

[27] C. R. González, J. E. Caminos, M. J. Vázquez et al., “Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue,” *The Journal of Physiology*, vol. 587, no. 14, pp. 3741–3750, 2009.

[28] M. Imbernon, L. Whyte, A. Diaz-Arteaga et al., “Regulation of GPR55 in rat white adipose tissue and serum LPI by nutritional status, gestation, gender and pituitary factors,” *Molecular and Cellular Endocrinology*, vol. 383, no. 1-2, pp. 159–169, 2014.

[29] G. Légrádi, C. H. Emerson, R. S. Ahima, J. S. Flier, and R. M. Lechan, “Leptin prevents fasting-induced suppression of prohydroprolactin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus,” *Endocrinology*, vol. 138, no. 6, pp. 2569–2576, 1997.

[30] M. Pardo, A. Roca-Rivada, O. Al-Massadi, L. M. Seoane, J. P. Camiña, and F. F. Casanueva, “Peripheral leptin and ghrelin receptors are regulated in a tissue-specific manner in activity-based anorexia,” *Peptides*, vol. 31, no. 10, pp. 1912–1919, 2010.

[31] K. M. Habegger, O. Al-Massadi, K. M. Heppner et al., “Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia,” *Gut*, vol. 63, no. 8, pp. 1238–1246, 2014.

[32] A. B. Crujeiras, M. A. Zuleta, P. Lopez-Lagarrea et al., “Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-losing program in obese patients,” *Metabolism: Clinical and Experimental*, vol. 63, no. 4, pp. 520–531, 2014.

[33] R. de la Iglesia, P. Lopez-Lagarrea, A. B. Crujeiras et al., “Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients,” *Clinical Endocrinology*, vol. 81, no. 2, pp. 306–311, 2014.

[34] T. Kuloglú, S. Aydin, M. N. Eren et al., “Irisin: a potentially candidate marker for myocardial infarction,” *Peptides*, vol. 55, pp. 85–91, 2014.

[35] B. Porteiro, A. Díaz-Ruíz, G. Martínez et al., “Ghrelin requires p53 to stimulate lipid storage in fat and liver,” *Endocrinology*, vol. 154, no. 10, pp. 3671–3679, 2013.

[36] O. Al-Massadi, A. B. Crujeiras, R. C. González et al., “Age, sex, and lactating status regulate ghrelin secretion and GOAT mRNA levels from isolated rat stomach,” *The American Journal of Physiology—Endocrinology and Metabolism*, vol. 299, no. 3, pp. E341–E350, 2010.

[37] L. L. Senin, O. Al-Massadi, C. Folgueira et al., “The gastric CBI receptor modulates ghrelin production through the mTOR pathway to regulate food intake,” *PLoS ONE*, vol. 8, no. 11, Article ID e80339, 2013.